Shattuck Labs (STTK) Expected to Announce Earnings on Thursday

Shattuck Labs (NASDAQ:STTK) is expected to be issuing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $0.1670 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 6:30 AM ET.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12). The firm had revenue of ($1.00) million for the quarter, compared to the consensus estimate of $0.17 million. On average, analysts expect Shattuck Labs to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shattuck Labs Price Performance

Shattuck Labs stock opened at $6.04 on Thursday. The business has a 50 day moving average of $4.52 and a 200-day moving average of $3.12. Shattuck Labs has a 1 year low of $0.69 and a 1 year high of $6.26. The company has a market capitalization of $432.22 million, a P/E ratio of -7.84 and a beta of 1.55.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Shattuck Labs in a research report on Thursday, January 22nd. Citigroup raised their price target on shares of Shattuck Labs from $4.00 to $7.00 and gave the company a “neutral” rating in a research note on Friday, March 13th. Needham & Company LLC assumed coverage on shares of Shattuck Labs in a report on Friday, March 6th. They set a “buy” rating and a $25.00 price target on the stock. TD Cowen reissued a “buy” rating on shares of Shattuck Labs in a research note on Friday, March 6th. Finally, Piper Sandler assumed coverage on Shattuck Labs in a report on Wednesday, January 28th. They issued an “overweight” rating and a $15.00 price objective for the company. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.50.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Virtu Financial LLC acquired a new position in shares of Shattuck Labs in the 3rd quarter valued at about $38,000. Squarepoint Ops LLC acquired a new stake in Shattuck Labs during the third quarter worth approximately $46,000. Dimensional Fund Advisors LP acquired a new stake in Shattuck Labs during the fourth quarter worth approximately $85,000. OMERS ADMINISTRATION Corp bought a new stake in Shattuck Labs in the fourth quarter worth approximately $97,000. Finally, Invesco Ltd. bought a new stake in Shattuck Labs in the fourth quarter worth approximately $103,000. 58.74% of the stock is owned by institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.